Filing identity and reporting period
The supplied filing is Edge Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2018, filed August 1, 2018. This does not match the request metadata naming PDS Biotechnology Corp.; the summary below reflects the filing text provided.
Business context and results
Edge was a clinical-stage biotechnology company with no commercial product revenue. After an interim analysis indicated a low probability that its Phase 3 NEWTON 2 trial of EG-1962 would meet its primary endpoint, the company discontinued the trial, stopped EG-1962 development, and suspended research on its other candidates. It began exploring strategic alternatives and reduced operations.
| Metric | Q2 2018 | Q2 2017 | Six months 2018 | Six months 2017 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Research and development | $2.5 million | $9.0 million | $15.3 million | $16.6 million |
| General and administrative | $3.3 million | $4.2 million | $8.0 million | $8.4 million |
| Restructuring expense | $6.6 million | — | $6.6 million | — |
| Net loss | $12.7 million | $13.5 million | $33.5 million | $25.7 million |
| Basic and diluted loss per share | $0.41 | $0.44 | $1.08 | $0.86 |
| Operating cash used | Not separately provided | Not separately provided | $21.8 million | $20.1 million |
Financial position and changes
- Cash and cash equivalents were $46.0 million at June 30, 2018, down from $88.1 million at December 31, 2017. The six-month cash decline was $42.1 million.
- Total assets were $47.2 million; current liabilities were $13.9 million. Current assets were $46.6 million. No current ratio or cash runway beyond management’s estimate is stated here.
- The company repaid its Hercules debt in June: $20.0 million principal, $0.9 million in back-end fees, and $0.1 million accrued interest. No debt remained at quarter-end.
- Six-month financing cash outflow was $20.3 million, mainly debt repayment and fees, partly offset by $0.7 million from option exercises. There was no investing cash flow in the period.
- Q2 R&D expense fell 72% year over year as clinical activity wound down. Six-month net loss increased 31%, reflecting restructuring charges, a $2.7 million equipment impairment, and higher net interest expense.
- Headcount fell from 37 to 15 during Q2. Management estimated approximately $6.5 million in annualized savings, potentially partly offset by increased outsourced-service costs.
Outlook, risks, and unusual items
- Management said existing cash was expected to fund anticipated requirements for at least 12 months from June 30, 2018, while cautioning that actual cash needs could differ. Spending was expected to decline as trial closeout and restructuring proceeded.
- The strategic review, advised by Piper Jaffray, could include a merger, asset or stock sale, acquisition, licensing transaction, or other business combination. There was no defined timetable or assurance of a transaction.
- NEWTON 2’s June update reported favorable Day 90 outcomes in 45% of EG-1962 patients versus 41% of oral nimodipine controls among 266 completed evaluations. The trial had been stopped after the prespecified interim analysis; the reported subgroup findings were not statistically significant. A final analysis of all 283 randomized and treated subjects was expected later in 2018.
- The restructuring charge included severance, financial-advisor fees, legal costs, and retention compensation. The company also recorded a $2.7 million impairment of manufacturing equipment no longer expected to be useful.
- A purported securities class action filed in April 2018 seeks unspecified damages concerning alleged omissions about the trial’s futility analysis. The company said it intended to defend the case; the outcome and timing were uncertain.
- Nasdaq had notified the company that it was not then compliant with audit committee requirements because the committee had two members; failure to regain compliance could lead to delisting. Strategic alternatives, workforce reductions, litigation, and cash preservation were significant uncertainties.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is for Edge Therapeutics, not PDS Biotechnology Corp.
- Review subsequent disclosures for the final NEWTON 2 analysis and any further development decisions concerning the pipeline.
- Track strategic-review outcomes, transaction terms, and the company’s remaining operating plans.
- Monitor cash use, restructuring payments, Oakwood’s accrued $2.5 million milestone obligation, and lease commitments.
- Check updates on the securities litigation and Nasdaq audit-committee listing compliance.